This grant from the National Institute on Aging (NIA) is for comprehensive functional validation of therapeutic targets for Alzheimer’s Disease-Related Dementias (ADRDs). It aims to de-risk translational research and accelerate novel ADRD therapies. Targets must stem from human genetic or tissue data. The program features an R61 stage to develop technologies for modulating targets and assessing consequences in disease models, followed by an R33 stage for rigorous, cross-laboratory validation of impact. This supports research across the ADRD spectrum (e.g., FTD, LBD, PDD, VCID, mixed dementias), emphasizing collaboration and excluding clinical trials.
Opportunity ID: 354648
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-NS-25-011 |
| Funding Opportunity Title: | Functional Target Validation for Alzheimer’s Disease-Related Dementias (R61/R33 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Grant |
| Category of Funding Activity: | Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.853 — Extramural Research Programs in the Neurosciences and Neurological Disorders |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | May 31, 2024 |
| Last Updated Date: | May 31, 2024 |
| Original Closing Date for Applications: | Nov 08, 2024 |
| Current Closing Date for Applications: | Nov 08, 2024 |
| Archive Date: | Dec 14, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public housing authorities/Indian housing authorities County governments Private institutions of higher education For profit organizations other than small businesses Small businesses Public and State controlled institutions of higher education City or township governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Independent school districts State governments Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This NOFO invites applications that propose the comprehensive functional validation of newly identified therapeutic target candidates for Alzheimer’s Disease-Related Dementias (ADRDs). This NOFO seeks to promote critical target validation approaches to help de-risk subsequent translational research and accelerate the advancement of novel therapies for ADRD. Target(s) or molecular pathway(s) to be considered for validation must have been already identified using tissue expression or genetic data generated in human samples. In its initial phase, this FOA provided support for up to two years (R61 stage) for the development of customized technologies, models, and protocols to modulate the expression or activity of target candidate(s) in cells or tissues and monitor their functional biological consequences in in vitro or in vivo disease models. Upon demonstration of technical feasibilities, a second phase (R33 stage) will carefully and reproducibly measure and cross-validate the impact of the target modulation in different modalities across collaborating laboratories using the NIH rigor and reproducibility guidelines. Applicants responding to this NOFO must address objectives for both the R61 and R33 phases and are expected to have a substantial collaborative effort between independents laboratories. This NOFO is not specific for any one or group within the ADRD spectrum of disorders. Disorders covered in these applications are frontotemporal degeneration (FTD), Lewy body dementias (LBD) (including dementia with Lewy bodies (DLB)), Parkinson disease dementia (PDD), vascular contributions to cognitive impairment and dementia (VCID), mixed dementias including the associated diagnostic challenges of multiples etiology dementias (MED). |
| Link to Additional Information: | https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-25-011.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH Grants Information
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 354648 Full Announcement-RFA-NS-25-011 -> RFA-NS-25-011-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH Grants Information grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00286810 | Oct 08, 2024 | Nov 08, 2024 | View |
Package 1
Mandatory forms
354648 RR_SF424_5_0-5.0.pdf
354648 PHS398_CoverPageSupplement_5_0-5.0.pdf
354648 RR_OtherProjectInfo_1_4-1.4.pdf
354648 PerformanceSite_4_0-4.0.pdf
354648 RR_KeyPersonExpanded_4_0-4.0.pdf
354648 RR_Budget10_3_0-3.0.pdf
354648 PHS398_ResearchPlan_5_0-5.0.pdf
354648 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
354648 RR_SubawardBudget10_30_3_0-3.0.pdf
354648 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
